Hepatorenal syndrome: pathophysiology and evidence-based management update.
epidemiology
hepatorenal syndrome
management
pathophysiology
Journal
Romanian journal of internal medicine = Revue roumaine de medecine interne
ISSN: 2501-062X
Titre abrégé: Rom J Intern Med
Pays: Germany
ID NLM: 9304507
Informations de publication
Date de publication:
01 Sep 2021
01 Sep 2021
Historique:
received:
05
01
2021
pubmed:
6
2
2021
medline:
15
12
2021
entrez:
5
2
2021
Statut:
epublish
Résumé
Hepatorenal syndrome (HRS) is a functional renal failure that develops in patients with advanced hepatic cirrhosis with ascites and in those with fulminant hepatic failure. The prevalence of HRS varies among studies but in general it is the third most common cause of acute kidney injury (AKI) in cirrhotic patients after pre-renal azotemia and acute tubular necrosis. HRS carries a grim prognosis with a mortality rate approaching 90% three months after disease diagnosis. Fortunately, different strategies have been proven to be successful in preventing HRS. Although treatment options are available, they are not universally effective in restoring renal function but they might prolong survival long enough for liver transplantation, which is the ultimate treatment. Much has been learned in the last two decades regarding the pathophysiology and management of this disease which lead to notable evolution in the HRS definition and better understanding on how best to manage HRS patients. In the current review, we will summarize the recent advancement in epidemiology, pathophysiology, and management of HRS.
Identifiants
pubmed: 33544554
pii: rjim-2021-0006
doi: 10.2478/rjim-2021-0006
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
227-261Informations de copyright
© 2021 Irtiza Hasan et al., published by Sciendo.
Références
1. Runyon BA Hepatorenal syndrome, 2020; Available from: https://www.uptodate.com/contents/hepatorenal-syndrome.
2. Velez J, Therapondos G, Juncos LA, Reappraising the spectrum of AKI and hepatorenal syndrome in patients with cirrhosis. Nat Rev Nephrol, 2020. 16: 137–155.
3. Wadei HM, Mai M, Ahsan N, Gonwa T, Hepatorenal Syndrome: Pathophysiology and Management. Clinical Journal of the American Society of Nephrology, 2006. 1: 1066–1079.
4. Tandon P, James M, Abraldes J, Karvellas C, Ye F, Pannu N, Relevance of New Definitions to Incidence and Prognosis of Acute Kidney Injury in Hospitalized Patients with Cirrhosis: A Retrospective Population-Based Cohort Study. PLoS One, 2016. 11: e0160394.
5. Tsien CD, Rabie R, Wong F Acute kidney injury in decompensated cirrhosis. Gut, 2013. 62: 131–7.
6. Angeli P, Ginès P, Wong F, Bernardi M, Boyer T, Gerbes A et al., Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites. J Hepatol, 2015. 62: 968–74.
7. Tariq R, Singal AK, Management of Hepatorenal Syndrome: A Review. J Clin Transl Hepatol, 2020. 8: 192–199.
8. Pickering JW, Endre ZH, The definition and detection of acute kidney injury. J Renal Inj Prev, 2014. 3: 21–5.
9. Angeli P, Garcia-Tsao G, Nadim MK, Parikh CR, News in pathophysiology, definition and classification of hepatorenal syndrome: A step beyond the International Club of Ascites (ICA) consensus document. J Hepatol, 2019. 71: 811–822.
10. Salerno F, Gerbes A, Ginès P, Wong F, Arroyo V, Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Postgrad Med J, 2008. 84: 662–70.
11. Arroyo V, Ginès P, Gerbes AL, Dudley FJ, Gentilini P, Laffi G, et al., Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club. Hepatology, 1996. 23:164–76.
12. Ginès P, Schrier RW, Renal failure in cirrhosis. N Engl J Med, 2009. 361: 1279–90.
13. Devuni D, Hepatorenal Syndrome. 2017; Available from: https://emedicine.medscape.com/article/178208-overview#a7.
14. Carvalho GC, Regis Cde A, Kalil JR, Cerqueira LA, Barbosa DS, Motta MP, et al., Causes of renal failure in patients with decompensated cirrhosis and its impact in hospital mortality. Ann Hepatol, 2012. 11:90–5.
15. Al-Khafaji A, Nadim MK, and Kellum JA, Hepatorenal Disorders. Chest, 2015. 148:550–558.
16. Low G, Alexander GJ, Lomas DJ, Hepatorenal syndrome: aetiology, diagnosis, and treatment. Gastroenterol Res Pract, 2015. 2015: 207012.
17. Salerno F, Cazzaniga M, Merli M, Spinzi M, Saibeni S, Salmi A, et al., Diagnosis, treatment and survival of patients with hepatorenal syndrome: a survey on daily medical practice. J Hepatol, 2011. 55:1241–8.
18. Martin-Llahi M, Guevara M, Torre A, Fagundes C, Restuccia T, Gilabert R, et al., Prognostic importance of the cause of renal failure in patients with cirrhosis. Gastroenterology, 2011. 140:488–496 e4.
19. Montoliu S, Ballesté B, Planas R, Alvarez MA, Rivera M, Miquel M, et al., Incidence and prognosis of different types of functional renal failure in cirrhotic patients with ascites. Clin Gastroenterol Hepatol, 2010. 8:616–22; quiz e80.
20. Angeli P, Morando F, Cavallin M, Piano S, Hepatorenal syndrome. Contrib Nephrol, 2011. 174:46–55.
21. Jamil K, Huang X, Lovelace B, Pham AT, Lodaya K, Wan G, The burden of illness of hepatorenal syndrome (HRS) in the United States: a retrospective analysis of electronic health records. J Med Econ, 2019. 22:421–429.
22. Rice JP, Skagen C, Said A, Liver transplant outcomes for patients with hepatorenal syndrome treated with pretransplant vasoconstrictors and albumin. Transplantation, 2011. 91:1141–7.
23. Jami K, Huang X, Lovelace B, Pham AT, Lodaya K, Wan G, The burden of illness of hepatorenal syndrome (HRS) in the United States: a retrospective analysis of electronic health records. Journal of Medical Economics, 2019. 22:421–429.
24. Fernandez-Sear J, Prieto J, Quiroga J, Zozaya JM, Cobos MA, Rodriguez-Eire JL et al., Systemic and regional hemodynamics in patients with liver cirrhosis and ascites with and without functional renal failure. Gastroenterology, 1989. 97:1304–12.
25. Schrier RW, Arroyo V, Bernardi M, Epstein M, Henriksen JH, Rodés J, Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology, 1988. 8:1151–7.
26. Jonassen TE, Marcussen N, Haugan K, Skyum H, Christensen S, Andreasen F et al., Functional and structural changes in the thick ascending limb of Henle's loop in rats with liver cirrhosis. Am J Physiol, 1997. 273:568–77.
27. Fede G, Privitera G, Tomaselli T, Spadaro L, Purrello F, Cardiovascular dysfunction in patients with liver cirrhosis. Ann Gastroenterol, 2015. 28:31–40.
28. Møller S, Henriksen JH, Cardiovascular complications of cirrhosis. Gut, 2008. 57:268–78.
29. Mandorfe M, Bota S, Schwabl P, Bucsics T, Pfisterer N, Kruzik M et al., Nonselective β blockers increase risk for hepatorenal syndrome and death in patients with cirrhosis and spontaneous bacterial peritonitis. Gastroenterology, 2014. 146: 1680–90.e1.
30. Kazory A, Ronco C, Hepatorenal Syndrome or Hepatocardiorenal Syndrome: Revisiting Basic Concepts in View of Emerging Data. Cardiorenal Med, 2019. 9:1–7.
31. Kim GH, Renal effects of prostaglandins and cyclooxygenase-2 inhibitors. Electrolyte Blood Press, 2008. 6:35–41.
32. Stadlbauer V, Wright GA, Banaji M, Mukhopadhya A, Mookerjee RP, Moore K, et al., Relationship between activation of the sympathetic nervous system and renal blood flow autoregulation in cirrhosis. Gastroenterology, 2008. 134:111–9.
33. Oliver JA, Verna EC, Afferent mechanisms of sodium retention in cirrhosis and hepatorenal syndrome. Kidney Int, 2010. 77:669–80.
34. Lang F, Tschernko E, Schulze E, Ottl I, Ritter M, Völkl H, et al., Hepatorenal reflex regulating kidney function. Hepatology, 1991. 14:590–4.
35. Ming Z, Lautt WW, Intrahepatic adenosine-mediated activation of hepatorenal reflex is via A1 receptors in rats. Can J Physiol Pharmacol, 2006. 84:1177–84.
36. Solis-Herruzo JA, Duran A, Favela V, Castellano G, JMadrid JL, Muñoz-Yagüe MT, et al., Effects of lumbar sympathetic block on kidney function in cirrhotic patients with hepatorenal syndrome. J Hepatol, 1987. 5:167–73.
37. Karagiannis AK, Nakouti T, Pipili C, Cholongitas E, Adrenal insufficiency in patients with decompensated cirrhosis. World J Hepatol, 2015. 7: 1112–24.
38. Chang Y, Qi X, Li Z, Wang F, Wang S, Zhang Z, et al., Hepatorenal syndrome: insights into the mechanisms of intra-abdominal hypertension. Int J Clin Exp Pathol, 2013. 6:2523–8.
39. Patel DM, Connor MJ, Intra-Abdominal Hypertension and Abdominal Compartment Syndrome: An Underappreciated Cause of Acute Kidney Injury. Adv Chronic Kidney Dis, 2016. 23:160–6.
40. Harman PK, Kron IL, McLachlan HD, Freedlender AE, Nolan SP, Elevated intra-abdominal pressure and renal function. Ann Surg, 1982. 196:594–7.
41. Watson RA, Owdieshell TR, Abdominal compartment syndrome. South Med J, 1998. 91:326–32.
42. Mikami O, Fujise K, Matsumoto S, Shingu K, M. Ashida M, Matsuda T, High intra-abdominal pressure increases plasma catecholamine concentrations during pneumoperitoneum for laparoscopic procedures. Arch Surg, 1998. 133:39–43.
43. Cade R, Wagemaker H, Vogel S, Mars D, Hood-Lewis D, Privette M, et al., Hepatorenal syndrome. Studies of the effect of vascular volume and intraperitoneal pressure on renal and hepatic function. Am J Med, 1987. 82:427–38.
44. Umgelter A., Reindl W, Franzen M, Lenhardt C, Huber W, Schmid RM, Renal resistive index and renal function before and after paracentesis in patients with hepatorenal syndrome and tense ascites. Intensive Care Med, 2009. 35(1):152–6.
45. Simonetto DA, Gines P, Kamath PS, Hepatorenal syndrome: pathophysiology, diagnosis, and management. Bmj, 2020. 370:2687.
46. Clàri J, Arroyo V, Moreau R, The Acute-on-Chronic Liver Failure Syndrome, or When the Innate Immune System Goes Astray. J Immunol, 2016. 197:3755–3761.
47. Wiest R, Das S, Cadelina G, Garcia-Tsao G, Milstien S, Groszmann RJ, Bacterial translocation in cirrhotic rats stimulates eNOS-derived NO production and impairs mesenteric vascular contractility. J Clin Invest, 1999. 104:1223–33.
48. Runyon BA., Squier S, Borzio M, Translocation of gut bacteria in rats with cirrhosis to mesenteric lymph nodes partially explains the pathogenesis of spontaneous bacterial peritonitis. J Hepatol, 1994. 21:792–6.
49. Solé C, Pose E, Solà E, Ginès P, Hepatorenal syndrome in the era of acute kidney injury. Liver Int, 2018. 38:1891–1901.
50. Lange CM Systemic inflammation in hepatorenal syndrome – A target for novel treatment strategies? Liver Int, 2019. 39:1199–1201.
51. Kalambokis GN., MouzakI A, Rodi M, Pappas K, Fotopoulos A, Xourgia X, et al., Rifaximin improves systemic hemodynamics and renal function in patients with alcohol-related cirrhosis and ascites. Clin Gastroenterol Hepatol, 2012. 10:815–8.
52. Alaniz C, Regal RE, Spontaneous bacterial peritonitis: a review of treatment options. P t, 2009. 34:204–10.
53. Shah N, Mohamed FE, Jover-Cobos M, Macnaughtan J, Davies N, Moreau R, et al., Increased renal expression and urinary excretion of TLR4 in acute kidney injury associated with cirrhosis. Liver Int, 2013. 33:398–409.
54. Zhang J, Liu J, Wu Y, Romeiro FG, Levi Sandri GB, X. Zhou X, et al., Effect of terlipressin on renal function in cirrhotic patients with acute upper gastrointestinal bleeding. Ann Transl Med, 2020. 8:340.
55. Cárdenas A, Ginès P, Uriz J, Bessa X, Salmerón JM, Mas A, et al., Renal failure after upper gastrointestinal bleeding in cirrhosis: incidence, clinical course, predictive factors, and short-term prognosis. Hepatology, 2001. 34:671–6.
56. Nazar A., Pereira GM, Guevara M, Martín-Llahi M, Pepin MN, Marinelli M, et al., Predictors of response to therapy with terlipressin and albumin in patients with cirrhosis and type 1 hepatorenal syndrome. Hepatology, 2010. 51:219–26.
57. Savale L, Weatherald J, Jaïs X, Vuillard C, Boucly A, M. Jevnikar M, et al., Acute decompensated pulmonary hypertension. Eur Respir Rev, 2017. 26:170092
58. Trawalé JM, Paradis V, Rautou PE, Francoz C, Escolano S, Sallée M, et al., The spectrum of renal lesions in patients with cirrhosis: a clinicopathological study. Liver Int, 2010. 30:725–32.
59. Alsaad AA, Wadei HM, Fractional excretion of sodium in hepatorenal syndrome: Clinical and pathological correlation. World J Hepatol, 2016. 8:1497–1501.
60. Belcher JM, Sanyal AJ, Peixoto AJ, Perazella MA, Lim J, Thiessen-Philbrook H, et al., Kidney biomarkers and differential diagnosis of patients with cirrhosis and acute kidney injury. Hepatology, 2014. 60: 622–32.
61. Verna EC, Brown RS, Farrand E, Pichardo EM, Forster CS, Sola-Del Valle DA, et al., Urinary neutrophil gelatinase-associated lipocalin predicts mortality and identifies acute kidney injury in cirrhosis. Dig Dis Sci, 2012. 57:2362–70.
62. Ring-Larsen H, Renal blood flow in cirrhosis: relation to systemic and portal haemodynamics and liver function. Scand J Clin Lab Invest, 1977. 37:635–42.
63. Ginès P, Guevara M, Arroyo V, Rodés J, Hepatorenal syndrome. Lancet, 2003. 362:1819–27.
64. Heidemann J, Bartels C, Berssenbrügge C, Schmidt H, Meister T, Hepatorenal syndrome: outcome of response to therapy and predictors of survival. Gastroenterol Res Pract, 2015. 2015:457613.
65. Kiser TH, Hepatorenal Syndrome. Int J Clin Med, 2014. 5:102–110.
66. Malespin MH, Risk of Nonsteroidal Anti-inflammatory Drugs and Safety of Acetaminophen in Patients with Advanced Liver Disease. Clin Liver Dis (Hoboken), 2018. 12:85–88.
67. Facciorusso A, Hepatorenal Syndrome Type 1: Current Challenges And Future Prospects. Ther Clin Risk Manag, 2019. 15:1383–1391.
68. EASL, EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol, 2010. 53: 397–417.
69. Walayat S, Martin D, Patel J, Ahmed U, Pai AU, et al., Role of albumin in cirrhosis: from a hospitalist's perspective. J Community Hosp Intern Med Perspect, 2017. 7:8–14.
70. Gluud LL, Christensen K, Christensen E, Krag A, Systematic review of randomized trials on vasoconstrictor drugs for hepatorenal syndrome. Hepatology, 2010. 51(2): p. 576–84.
71. Runyon BA, Introduction to the revised American Association for the Study of Liver Diseases Practice Guideline management of adult patients with ascites due to cirrhosis 2012. Hepatology, 2013. 57:1651–3.
72. De Mattos ÁZ, de Mattos AA, Méndez-Sánchez N, Hepatorenal syndrome: Current concepts related to diagnosis and management. Ann Hepatol, 2016. 15: 474–81.
73. Chen TA, Tsao YC, Chen A, Lo GH, Lin CK, Yu HC, et al., Effect of intravenous albumin on endotoxin removal, cytokines, and nitric oxide production in patients with cirrhosis and spontaneous bacterial peritonitis. Scand J Gastroenterol, 2009. 44: 619–25.
74. Yeo CM, Garcia-Tsao G, Vasoconstrictor Therapy for Hepatorenal Syndrome. In: Ascites, Hyponatremia and Hepatorenal Syndrome: Progress in Treatment., Karger, Basel, 2011:149–162.
75. Moreau R, Lebrec D, The use of vasoconstrictors in patients with cirrhosis: Type 1 HRS and beyond. Hepatology, 2006. 43:385–394.
76. Sanyal AJ, Boyer T, Garcia-Tsao G, Regenstein F, Rossaro L, Appenrodt B, et al., A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome. Gastroenterology, 2008. 134:1360–8.
77. Boyer TD, Medicis JJ, Pappas SC, Potenziano J, Jamil K, A randomized, placebo-controlled, double-blind study to confirm the reversal of hepatorenal syndrome type 1 with terlipressin: the REVERSE trial design. Open Access Journal of Clinical Trials, 2012. 4:39–49.
78. Jamil K, Pappas SC, Wong F, Sanyal AJ, Verified Hepatorenal Syndrome Reversal As A Robust Multi-Component Primary End Point: The CONFIRM Study Trial Design. Open Access Journal of Clinical Trials, 2019. 11:67–73.
79. Israelsen M, Dahl EK, Madsen BS, Wiese S, Bendtsen F, Møller S, et al., Dobutamine reverses the cardio-suppressive effects of terlipressin without improving renal function in cirrhosis and ascites: a randomized controlled trial. Am J Physiol Gastrointest Liver Physiol, 2020. 318:G313–g321.
80. Piano S, Gambino C, Vettore E, Calvino V, Tonon M, Boccagni P, et al., Response to Terlipressin and Albumin Is Associated With Improved Liver Transplant Outcomes in Patients With Hepatorenal Syndrome. Hepatology, 2020. doi: 10.1002/hep.31529
81. Krishna R, Raj J, Dev D, Prasad SC, Reghu R, V SO, A study on clinical outcomes of combination of terlipressin and albumin in Hepatorenal Syndrome. Scand J Gastroenterol, 2020. 55:860–864.
82. Sanyal AJ, Boyer TD, Frederick RT, Wong F, Rossaro L, Araya V, et al., Reversal of hepatorenal syndrome type 1 with terlipressin plus albumin vs. placebo plus albumin in a pooled analysis of the OT-0401 and REVERSE randomised clinical studies. Aliment Pharmacol Ther, 2017. 45:1390–1402.
83. Wong F, Pappas SC, Boyer TD, Sanyal AJ, Bajaj JS, Escalante S, et al., Terlipressin Improves Renal Function and Reverses Hepatorenal Syndrome in Patients With Systemic Inflammatory Response Syndrome. Clin Gastroenterol Hepatol, 2017. 15:266–272.e1.
84. Boyer TD, Sanyal AJ, Wong F, Frederick RT, Lake JR, O'Leary JG, et al., Terlipressin Plus Albumin Is More Effective Than Albumin Alone in Improving Renal Function in Patients With Cirrhosis and Hepatorenal Syndrome Type 1. Gastroenterology, 2016. 150:1579–1589 e2.
85. Narahara Y, Kanazawa H, Sakamoto C, Maruyama H, Yokosuka O, Mochida S, et al., The efficacy and safety of terlipressin and albumin in patients with type 1 hepatorenal syndrome: a multicenter, open-label, explorative study. J Gastroenterol, 2012. 47: 313–20.
86. Boyer TD, Sanyal AJ, Garcia-Tsao G, Blei A, Carl D, Bexon AS, et al., Predictors of response to terlipressin plus albumin in hepatorenal syndrome (HRS) type 1: relationship of serum creatinine to hemodynamics. J Hepatol, 2011. 55:315–21.
87. Muñoz LE, Alcalá EG, Cordero P, Martínez MA, Vázquez NY, Galindo S, et al., Reversal of hepatorenal syndrome in cirrhotic patients with terlipressin plus albumin. First experience in Mexico. Ann Hepatol, 2009. 8:207–11.
88. Sanyal AJ, Boyer T, Garcia-Tsao G, Regenstein F, Rossaro L, Appenrodt B, et al., A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome. Gastroenterology, 2008. 134:1360–8.
89. Arab JP, Claro JC, Arancibia JP, Contreras J, Gómez F, Muñoz C, et al., Therapeutic alternatives for the treatment of type 1 hepatorenal syndrome: A Delphi technique-based consensus. World J Hepatol, 2016. 8:1075–86.
90. Fagundes C, Ginès P, Hepatorenal syndrome: a severe, but treatable, cause of kidney failure in cirrhosis. Am J Kidney Dis, 2012. 59: 874–85.
91. Wan S, Wan X, Zhu Q, Peng J, A comparative study of high-or low-dose terlipressin therapy in patients with cirrhosis and type 1 hepatorenal syndrome. Zhonghua Gan Zang Bing Za Zhi, 2014. 22:349–53.
92. Cavallin M, Piano S, Romano A, Fasolato S, Frigo AC, Benetti G, et al., Terlipressin given by continuous intravenous infusion versus intravenous boluses in the treatment of hepatorenal syndrome: A randomized controlled study. Hepatology, 2016. 63:983–92.
93. von Kalckreuth V, Glowa F, Geibler M, Lohse AW, Denzer UW, Terlipressin in 30 patients with hepatorenal syndrome: results of a retrospective study. Z Gastroenterol, 2009. 47:21–6.
94. Abdel-Razik A, Mousa N, Abdelsalam M, Abdelwahab A, Tawfik M, Tawfik AM, et al., Endothelin-1/Nitric Oxide Ratio as a Predictive Factor of Response to Therapy With Terlipressin and Albumin in Patients With Type-1 Hepatorenal Syndrome. Front Pharmacol, 2020. 11:9.
95. Saif RU, Dar HA, Sofi SM, Andrabi MS, Javid G, Zargar SA, Noradrenaline versus terlipressin in the management of type 1 hepatorenal syndrome: A randomized controlled study. Indian J Gastroenterol, 2018. 37:424–429.
96. Goyal O, Sidhu SS, Sehgal N, Puri S, Noradrenaline is as Effective as Terlipressin in Hepatorenal Syndrome Type 1: A Prospective, Randomized Trial. J Assoc Physicians India, 2016. 64:30–35.
97. Sarwar S, Khan AA, Hepatorenal syndrome:Response to terlipressin and albumin and its determinants. Pak J Med Sci, 2016. 32:274–8.
98. Altun R, Korkmaz M, Yıldırım E, Öcal S, Akbaş E, Selçuk H, Terlipressin and albumin for type 1 hepatorenal syndrome: does bacterial infection affect the response? Springerplus, 2015. 4:06.
99. Ghosh S, Choudhary NS, Sharma AK, Singh B, Kumar P, Agarwal R, et al., Noradrenaline vs terlipressin in the treatment of type 2 hepatorenal syndrome: a randomized pilot study. Liver Int, 2013. 33:1187–93.
100. Hinz M, Wree A, Jochum C, Bechmann LP, Saner F, Gerbes AL, et al., High age and low sodium urine concentration are associated with poor survival in patients with hepatorenal syndrome. Ann Hepatol, 2013. 12:92–9.
101. Velez JC, Nietert PJ, Therapeutic response to vasoconstrictors in hepatorenal syndrome parallels increase in mean arterial pressure: a pooled analysis of clinical trials. Am J Kidney Dis, 2011. 58:928–38.
102. Cavalli M, Kamath PS, Merli M, Fasolato S, Toniutto P, Salerno F, et al., Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: A randomized trial. Hepatology, 2015. 62:567–74.
103. Triantos CK, Samonakis D, Thalheimer U, Cholongitas E, Senzolo M, Marelli L, et al., Terlipressin therapy for renal failure in cirrhosis. Eur J Gastroenterol Hepatol, 2010. 22:481–6.
104. Olivera-Martinez M, Sayles H, Vivekanandan R, D'Souza S, Florescu MC, Hepatorenal syndrome: are we missing some prognostic factors? Dig Dis Sci, 2012. 57:210–4.
105. Barbano B, Sardo L, Gigante A, Gasperini ML, Liberatori M, Giraldi GD, et al., Pathophysiology, diagnosis and clinical management of hepatorenal syndrome: from classic to new drugs. Curr Vasc Pharmacol, 2014. 12:125–35.
106. Lee HJ, Oh MJ, A case of peripheral gangrene and osteomyelitis secondary to terlipressin therapy in advanced liver disease. Clin Mol Hepatol, 2013. 19:179–84.
107. Sagi SV, Mittal S, Kasturi KS, Sood GK, Terlipressin therapy for reversal of type 1 hepatorenal syndrome: a meta-analysis of randomized controlled trials. J Gastroenterol Hepatol, 2010. 25:880–5.
108. Rodríguez E, Elia C, Solà E, Barreto R, Graupera I, Andrealli A, et al., Terlipressin and albumin for type-1 hepatorenal syndrome associated with sepsis. J Hepatol, 2014. 60:955–61.
109. Kalambokis GN, Pappas K, Tsianos EV, Terlipressin improves pulmonary pressures in cirrhotic patients with pulmonary hypertension and variceal bleeding or hepatorenal syndrome. Hepatobiliary Pancreat Dis Int, 2012. 11:434–7.
110. Gupta K, Rani P, Rohatgi A, Verma M, Handa S, Dalal K, et al., Noradrenaline for reverting hepatorenal syndrome: a prospective, observational, single-center study. Clin Exp Gastroenterol, 2018. 11:317–324.
111. Arora V, Maiwall M, Rajan V, Jindal A, Muralikrishna S, Kumar G, et al., Terlipressin Is Superior to Noradrenaline in the Management of Acute Kidney Injury in Acute on Chronic Liver Failure. Hepatology, 2020. 71:600–610.
112. Singh V, Ghosh S, Singh B, Kumar P, Sharma N, Bhalla A, et al., Noradrenaline vs. terlipressin in the treatment of hepatorenal syndrome: a randomized study. J Hepatol, 2012. 56:1293–8.
113. Esrailian E, Pantangco ER, Kyulo NL, Hu KQ, Runyon BA, Octreotide/Midodrine therapy significantly improves renal function and 30-day survival in patients with type 1 hepatorenal syndrome. Dig Dis Sci, 2007. 52:742–8.
114. Skagen C, Einstein M, Lucey MR, Said A, Combination treatment with octreotide, midodrine, and albumin improves survival in patients with type 1 and type 2 hepatorenal syndrome. J Clin Gastroenterol, 2009. 43:680–5.
115. Facciorusso A, Chandar AK, Murad MH, Prokop LJ, Muscatiello N, Kamath PS, et al., Comparative efficacy of pharmacological strategies for management of type 1 hepatorenal syndrome: a systematic review and network meta-analysis. Lancet Gastroenterol Hepatol, 2017. 2:94–102.
116. Nassar JR AP, Farias AQ, LA D'Albuquerque, Carrilho FJ, Malbouisson LM, Terlipressin versus norepinephrine in the treatment of hepatorenal syndrome: a systematic review and meta-analysis. PLoS One, 2014. 9:e107466.
117. Sharma P, Kumar A, Shrama BC, Sarin SK, An open label, pilot, randomized controlled trial of noradrenaline versus terlipressin in the treatment of type 1 hepatorenal syndrome and predictors of response. Am J Gastroenterol, 2008. 103:1689–97.
118. Alessandria C, Ottobrelli A, Debernardi-Venon W, Todros L, Cerenzia MT, S. Martini S, et al., Noradrenalin vs terlipressin in patients with hepatorenal syndrome: a prospective, randomized, unblinded, pilot study. J Hepatol, 2007. 47:499–505.
119. Srivastav S, Shalimar, Vishnubhatla S, Prakash S, Sharma H, Thakur B, et al., Randomized Controlled Trial Comparing the Efficacy of Terlipressin and Albumin with a Combination of Concurrent Dopamine, Furosemide, and Albumin in Hepatorenal Syndrome. J Clin Exp Hepatol, 2015. 5:276–85.
120. Kiser TN, Fish DN, Obritsch MD, Jung R, MacLaren R, Parikh CR, Vasopressin, not octreotide, may be beneficial in the treatment of hepatorenal syndrome: a retrospective study. Nephrol Dial Transplant, 2005. 20:1813–20.
121. Zhang TF, Yang N, Zhao G, Liu LN, Wang YD, Duan ZJ, Meta-analysis of terlipressin in treatment of hepatorenal syndrome: an update. Zhonghua Yi Xue Za Zhi, 2009. 89:1970–4.
122. Wang L, Long Y, Li KX, Xu GS, Pharmacological treatment of hepatorenal syndrome: a network meta-analysis. Gastroenterol Rep (Oxf), 2020. 8: 111–118.
123. Testino G, Hepatorenal syndrome: role of the transjugular intrahepatic stent shunt in real life practice. Clujul Med, 2017. 90: 464–465.
124. Song T, Rössle M, He F, Liu F, Guo X, Qi X, Transjugular intrahepatic portosystemic shunt for hepatorenal syndrome: A systematic review and meta-analysis. Dig Liver Dis, 2018. 50: 323–330.
125. Brensing KA, Textor J, Perz J, Schiedermaier P, Raab P, Strunk H, et al., Long term outcome after transjugular intrahepatic portosystemic stent-shunt in non-transplant cirrhotics with hepatorenal syndrome: a phase II study. Gut, 2000. 47: 288–95.
126. Guevara M, P. Ginès P, Bandi JC, Gilabert R, Sort P, W. Jiménez W, et al., Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome: effects on renal function and vasoactive systems. Hepatology, 1998. 28: 416–22.
127. Malinchoc M, Kamath PS, Gordon FD, Peine CJ, Rank J, ter Borg PC, A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology, 2000. 31: 864–71.
128. Rössle M, Gerbes AL, TIPS for the treatment of refractory ascites, hepatorenal syndrome and hepatic hydrothorax: a critical update. Gut, 2010. 59: 988–1000.
129. Mitzner SR, Stange J, Klammt S, Risler T, Erley CM, Bader BD, et al., Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: results of a prospective, randomized, controlled clinical trial. Liver Transpl, 2000. 6: 277–86.
130. Mitzner SR, Klammt S, Peszynski P, Hickstein H, Korten G, Stange J, et al., Improvement of multiple organ functions in hepatorenal syndrome during albumin dialysis with the molecular adsorbent recirculating system. Ther Apher, 2001. 5:417–22.
131. Bañares R, Nevens F, Larsen FS, Jalan R, Albillos A, Dollinger M, et al., Extracorporeal albumin dialysis with the molecular adsorbent recirculating system in acute-on-chronic liver failure: the RELIEF trial. Hepatology, 2013. 57:1153–62.
132. Wong F, Raina, Richardson R, Molecular adsorbent recirculating system is ineffective in the management of type 1 hepatorenal syndrome in patients with cirrhosis with ascites who have failed vasoconstrictor treatment. Gut, 2010. 59: 381–6.
133. Sourianarayanane A, Raina R, Garg G, McCullough AJ, O'Shea RS, Management and outcome in hepatorenal syndrome: need for renal replacement therapy in non-transplanted patients. Int Urol Nephrol, 2014. 46: 793–800.
134. Allegretti AS, Parada XV, Eneanya ND, Gilligan H, Xu D, Zhao S, et al., Prognosis of Patients with Cirrhosis and AKI Who Initiate RRT. Clin J Am Soc Nephrol, 2018. 13: 16–25.
135. Capling RK, Bastani B, The clinical course of patients with type 1 hepatorenal syndrome maintained on hemodialysis. Ren Fail, 2004. 26:563–8.
136. Epstein M, Hepatorenal syndrome: emerging perspectives. Semin Nephrol, 1997. 17: 563–75.
137. Davenport A, Will EJ, Davidson AM, Improved cardiovascular stability during continuous modes of renal replacement therapy in critically ill patients with acute hepatic and renal failure. Crit Care Med, 1993. 21: 328–38.
138. Nand N, Verma P, Jain D, Comparative Evaluation of Continuous Veno-venous Hemodiafiltration and Continuous Arterio-Venous Hemodiafiltration in Patients of Hepatic Failure and / or Hepatorenal Syndrome. J Assoc Physicians India, 2019. 67:39–42.
139. Boyer TD, Sanyal AJ, Garcia-Tsao G, Regenstein F, Rossaro L, Appenrodt B, et al., Impact of liver transplantation on the survival of patients treated for hepatorenal syndrome type 1. Liver Transpl, 2011. 17: 1328–32.
140. Nadim MK., Sung RS, Davis CL, Andreoni KA, Biggins SW, Danovitch GW, et al., Simultaneous liver-kidney transplantation summit: current state and future directions. Am J Transplant, 2012. 12: 2901–8.
141. Ruiz RH, Kunitake H, Wilkinson AH, Danovitch GM, Farmer DG, Ghobrial RM, et al., Long-term analysis of combined liver and kidney transplantation at a single center. Arch Surg, 2006. 141: 735–41; discussion 741–2.
142. Wadei HM, Lee DD, Croome KP, Mai ML, Golan E, Brotman R, et al., Early Allograft Dysfunction After Liver Transplantation Is Associated With Short-and Long-Term Kidney Function Impairment. Am J Transplant, 2016. 16: 850–9.
143. Lee JP, Kwon HY, Park JI, Yi NJ, Suh KS, Lee HW, et al., Clinical outcomes of patients with hepatorenal syndrome after living donor liver transplantation. Liver Transpl, 2012. 18: 1237–44.
144. Rodriguez E, Pereira GH, Solà E, Elia C, Barreto R, Pose E, et al., Treatment of type 2 hepatorenal syndrome in patients awaiting transplantation: Effects on kidney function and transplantation outcomes. Liver Transpl, 2015. 21: 1347–54.
145. Thomson MJ, Taylor A, Sharma P, Lok AS, Tapper EB, Limited Progress in Hepatorenal Syndrome (HRS) Reversal and Survival 2002–2018: A Systematic Review and Meta-Analysis. Dig Dis Sci, 2020. 65: 1539–1548.
146. Snowdon VK., Lachlan NJ, Hoy AM, Hadoke PW, Semple SI, Patel D, et al., Serelaxin as a potential treatment for renal dysfunction in cirrhosis: Preclinical evaluation and results of a randomized phase 2 trial. PLoS Med, 2017. 14: e1002248.
147. Stine JG, Wang J, Cornella SL, Behm BW, Henry Z, Shah NL, et al., Treatment of Type-1 Hepatorenal Syndrome with Pentoxifylline: A Randomized Placebo Controlled Clinical Trial. Ann Hepatol, 2018. 17: 300–306.
148. Akriviadis E, Botla R, Briggs W, Han S, Reynolds T, Shakil O, Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. Gastroenterology, 2000. 119: 1637–48.
149. Martin-Llahi M, Pepin MN, Guevara M, Diaz F, Torre A, Monescillo A, et al., Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study. Gastroenterology, 2008. 134:1352–9.
150. Nguyen-Tat M, Jäger J, Rey JW, Nagel M, Labenz C, Wörns MA, et al., Terlipressin and albumin combination treatment in patients with hepatorenal syndrome type 2. United European Gastroenterol J, 2019. 7: 529–537.
151. Fabriz F, Aghemo A, Messa P, Hepatorenal syndrome and novel advances in its management. Kidney Blood Press Res, 2013. 37(6): p. 588–601.
152. Lata J, Hepatorenal syndrome. World J Gastroenterol, 2012. 18: 4978–84.
153. Hanish SI, Samaniego M, Mezrich JD, Foley DP, Leverson GE, Lorentzen DF, et al., Outcomes of simultaneous liver/kidney transplants are equivalent to kidney transplant alone: a preliminary report. Transplantation, 2010. 90: 52–60.
154. Hiruy A, J. Nelson J, Zori A, Morelli G, Cabrera R, Kamel A, Standardized approach of albumin, midodrine and octreotide on hepatorenal syndrome treatment response rate. Eur J Gastroenterol Hepatol, 2020.
155. Kade G, Lubas A, Spaleniak S, Wojtecka A, Leśniak, Literacki, S et al., Application of the Molecular Adsorbent Recirculating System in Type 1 Hepatorenal Syndrome in the Course of Alcohol-Related Acute on Chronic Liver Failure. Med Sci Monit, 2020. 26: e923805.
156. Park GC, Hwang S, Jung DH, Song GW, Ahn CS, Kim KH, et al., Is renal replacement therapy necessary in deceased donor liver transplantation candidates with hepatorenal syndrome?: a 2-year experience at a high-volume center. Ann Surg Treat Res, 2020. 98: 102–109.
157. Nguyen-Tat M, Götz E, Scholz-Kreisel P, Ahrens J, Sivanathan V, Schattenberg J, et al., [Response to Terlipressin and albumin is associated with improved outcome in patients with cirrhosis and hepatorenal syndrome]. Dtsch Med Wochenschr, 2015. 140: e21–6.
158. Wong F, Leung W, Al Beshir M, Marquez M, Renner EL, Outcomes of patients with cirrhosis and hepatorenal syndrome type 1 treated with liver transplantation. Liver Transpl, 2015. 21:300–7.
159. Tavakkoli H, Yazdanpanah K, M. Mansourian, Noradrenalin versus the combination of midodrine and octreotide in patients with hepatorenal syndrome: randomized clinical trial. Int J Prev Med, 2012. 3: 764–9.
160. Testr AG, Wongseelashote S, Angus PW, Gow PJ, Long-term outcome of patients treated with terlipressin for types 1 and 2 hepatorenal syndrome. J Gastroenterol Hepatol, 2008. 23: 1535–40.
161. Neri S, Pulvirenti D, Malaguarnera M, Cosimo BM, Bertino G, Ignaccolo L, et al., Terlipressin and albumin in patients with cirrhosis and type I hepatorenal syndrome. Dig Dis Sci, 2008. 53: 830–5.